

## **The relationship between glycaemia, cognitive function, structural brain outcomes and dementia: A Mendelian randomization study in the UK Biobank**

Victoria Garfield, PhD<sup>1</sup>, Aliko-Eleni Farmaki, PhD<sup>1</sup>, Ghazaleh Fatemifar, PhD<sup>3,5</sup>,  
Sophie V. Eastwood, MRCP<sup>1</sup>, Rohini Mathur, PhD<sup>2</sup>, Christopher T. Rentsch, PhD<sup>2</sup>,  
Spiros Denaxas, PhD<sup>3,4,5</sup>, Krishnan Bhaskaran, PhD<sup>2</sup>, Liam Smeeth, PhD<sup>2</sup>, Nish  
Chaturvedi, MD<sup>1</sup>

<sup>1</sup>MRC Unit for Lifelong Health and Ageing at UCL, Institute of Cardiovascular Science, University College London, 1-19 Torrington Place, London, WC1E 7HB

<sup>2</sup>Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT

<sup>3</sup>Institute of Health Informatics, University College London, 222 Euston Road, NW1 2DA

<sup>4</sup>Alan Turing Institute, London, UK

<sup>5</sup>Health Data Research UK (HDR UK), London, NW1 2DA

Corresponding author: Dr Victoria Garfield, 1-19 Torrington Place, London, WC1E 7HB, United Kingdom, Tel.: +442035495589, email: [v.garfield@ucl.ac.uk](mailto:v.garfield@ucl.ac.uk)

Word count: 2,625

Number of tables: 3

## Abstract

**Aims:** To investigate the relationship between glycaemia and cognitive function, brain structure and incident dementia using bidirectional Mendelian randomisation (MR).

**Methods:** UK Biobank (n~500,000) individuals, aged 40-69 years at baseline. Our exposures were genetic instruments for type-2 diabetes (163 variants) and HbA<sub>1c</sub> (52 variants) and our outcomes were reaction time (RT - milliseconds), visual memory (number of incorrect responses), hippocampal and white matter hyperintensity volumes (both mm<sup>3</sup>), Alzheimer's disease (AD). To study potential bidirectional effects, we then investigated the associations between genetic variants for RT (43 variants) and clinical type-2 diabetes and measured HbA<sub>1c</sub>. We used conventional inverse-variance weighted (IVW) MR, alongside standard MR sensitivity analyses.

**Results:** Using IVW, genetic liability to type-2 diabetes was not associated with reaction time (exponentiated  $\beta=1.00$ , 95%CI=1.00; 1.00), visual memory (exp $\beta=1.00$ , 95%CI=0.99; 1.00), white matter hyperintensity volume (exp $\beta=0.98$ , 95%CI=0.93; 1.03), hippocampal volume (coefficient mm<sup>3</sup>=0.00, 95%CI=-0.01; 0.01) or risk of AD (OR 0.97, 95%CI=0.89; 1.06). HbA<sub>1c</sub> was not associated with reaction time (exp $\beta=1.01$ , 95%CI=1.00; 1.01), white matter hyperintensity volume (exp $\beta=0.88$ , 95%CI=0.73; 1.07), hippocampal volume (coefficient=-0.02, 95%CI=-0.10; 0.06), risk of AD (OR 0.94, 95%CI=0.47; 1.86), but HbA<sub>1c</sub> was associated with visual memory (exp $\beta=1.06$ , 95%CI=1.05; 1.07) using a weighted median approach. IVW showed no evidence that reaction time was associated with diabetes (OR 0.96, 95%CI=0.63; 1.46) or HbA<sub>1c</sub> (coefficient=-0.08, 95%CI=-0.57; 0.42). MR-Egger intercept p-values indicated no major issues with unbalanced horizontal pleiotropy (all p>0.05).

**Conclusions:** Overall, we observed little evidence of causal associations between glycaemia and cognition, structural brain and dementia phenotypes.

**Keywords:** Alzheimer's dementia, cognitive function, diabetes, glycaemia, brain health, Mendelian randomization.

## **Abbreviations**

Alzheimer's dementia (AD)

Benjamini-Hochberg false discovery rate (BH-FDR)

Genome-wide association study (GWAS)

Hippocampal volume (HV)

Hospital episode statistics (HES)

International Classification of Diseases (ICD)

Inverse variance weighted (IVW)

Magnetic resonance imaging (MRI)

Mendelian randomization (MR)

Quality control (QC)

Reaction time (RT)

Simulation extrapolation (SIMEX)

UK Biobank (UKB)

Visual memory (VM)

Weighted median Estimator (WME)

White matter hyperintensity volume (WMHV)

## Introduction

Epidemiological studies largely suggest that hyperglycaemia, diabetes and insulin resistance are associated with poorer brain health [1, 2]. The exact mechanisms remain elusive, limiting intervention attempts as it is unclear whether hyperglycaemia per se is the culprit or if vascular risk factors (e.g. hypertension, dyslipidaemia, inflammation) mediate the association between diabetes and poorer brain outcomes. It is also not known whether the associations between hyperglycaemic conditions and brain outcomes are causal in nature. Some evidence also advocates a bidirectional relationship, implicating a vicious cycle whereby diabetes could result in dementia and dementia could then trigger further diabetes complications [3].

Mendelian randomization (MR) overcomes some of the limitations of causal interpretation in observational studies. So far, MR studies in this area have focussed solely on Alzheimer's dementia, with all three reporting no impact of diabetes [4–6]. Pathways to cognitive decline and dementia involve a combination of vascular and neurocognitive mechanisms that may act either independently or in concert [7]. Diabetes is more related to the vascular pathways but there is evidence that it also has neurotoxic consequences [8]. There have been no previous MR studies that have investigated HbA<sub>1c</sub> and subclinical measures of brain health such as cognitive function or structural brain abnormalities. No MR studies have investigated whether the bidirectional association may be causal in nature. Thus, the present study used i) genetic instruments for type-2 diabetes and HbA<sub>1c</sub>, to examine the relationship with cognitive function, structural brain measures and Alzheimer's dementia (AD); and ii) where possible, genetic instruments for cognitive function to investigate whether the relationship with diabetes or HbA<sub>1c</sub> might be bidirectional.

## Methods

### *Study design*

Two-sample MR (a design that exploits genome-wide association summary statistics derived in non-overlapping samples) was used to mitigate biased results due to the 'winners' curse' (the over-estimation of genetic associations which are common in the one-sample MR setting) because it is neither necessary, nor desirable, that the genetic variants to be instrumented be derived from the same sample as the one under study [9]. An important advantage of using two-sample MR methods is that it

allows sensitivity analyses to identify unbalanced horizontal pleiotropy (described under *Statistical analyses*), which is crucial to check MR assumptions. In our two-sample MR approach, there was some sample overlap for diabetes and cognitive function (reaction time), but not for the HbA<sub>1c</sub> genetic variants.

### *Sample*

Full details of the UK Biobank (UKB) cohort have been described elsewhere [10]. Briefly, UKB consists of 500,000 males and females from the general UK population, aged 40-69 years at baseline (2006-2010). There was a maximum of 349,326 participants of European ancestry with both genotype and all the phenotypes of interest in this study (Figure 1); 54% were male and participants' mean age was 56.7 years ( $\pm 8.0$  years).

### *Genotyping and quality control (QC) in UKB*

487,409 UKB participants were genotyped using one of two customised genome-wide arrays that were imputed to a combination of the UK10K, 1000 Genomes Phase 3 and the Haplotype Reference Consortium (HRC) reference panels, which resulted in 93,095,623 autosomal variants [11]. We then applied additional variant level QC and excluded genetic variants with: Fisher's exact test  $< 0.3$ , minor allele frequency (MAF)  $< 1\%$  and a missing call rate of  $\geq 5\%$ . Individual-level QC meant that we excluded participants with: excessive or minimal heterozygosity, more than 10 putative third-degree relatives as per the kinship matrix, no consent to extract DNA, sex mismatches between self-reported and genetic sex, missing QC information and non-European ancestry.

### *Outcomes: baseline cognitive function, structural brain magnetic resonance imaging (MRI) and dementia*

UKB administered five baseline cognitive assessments to all participants, via a computerised touch-screen interface, all of which are described in detail elsewhere [12]. In the *visual memory* assessment, respondents were asked to correctly identify matches from six pairs of cards after they had memorised their positions. Then, the number of incorrect matches (number of attempts made to correctly identify the pairs) was recorded, with a greater number reflective of a poorer visual memory. Reaction time (in milliseconds) was recorded as the mean time participants took to

correctly identify matches in a 12-round game of ‘Snap’. A higher score on this test indicated a slower (poorer) reaction time. Both of these variables were positively skewed and therefore, reaction time scores were transformed using the natural logarithmic function  $[\ln(x)]$ , whilst visual memory was transformed using  $[\ln(x+1)]$ .

Structural brain MRI scans were performed by UK in a subsample of participants using standard protocols, as published previously [13]. The post-processed measures derived by UK and used in this study included: hippocampal volume normalised for head size and total volume ( $\text{mm}^3$ ), and volume of white matter hyperintensities (WMH,  $\text{mm}^3$ ). WMH volume was log-transformed as it was positively skewed. The number of participants with WMH volume data was  $n=21,391$  and  $n=20,201$  for hippocampal volume (Figure 1). We report results in  $\text{mm}^3$  for hippocampal volume and exponentiated betas and percentages for WMH volume. Alzheimer’s disease (2006-2017) was captured using ICD-10 codes (alphanumeric codes to classify symptoms, diseases, injuries, infections and disorders) in linked hospital episode statistics (HES) data, as well as from death certification, primary care, self-report and nurse interview and these algorithmically-defined outcomes were provided by UKB.

### *Statistical analyses*

Analyses were performed using a combination of the *mrrobust* package in STATA, version 15, the *MendelianRandomization* R package, using RStudio version 1.1.456 and PLINK version 1.9.

### Selection of genetic variants for exposures

For diabetes, 163 independent genetic variants were chosen from the genome-wide association study (GWAS) by Mahajan et al. [14], in which they combined data across 32 studies, including 74,124 diabetes cases and 824,006 controls of European ancestry. In our sample these variants explained  $\sim 1.5\%$  (pseudo- $R^2=0.015$ ) of the variance in 14,010 diabetes cases. For bidirectional MR analyses we used 43 SNPs associated with reaction time (RT) from a recent GWAS [15] of 330,069 UKB participants with both phenotype and genotype data available. The RT variants explained 0.3% of the variance in RT in our study and the instrument had an F-statistic of 24.0. More details can be found in the original GWAS papers [14–16].

We harmonised genetic variants from the published GWAS with UKB by aligning the effect alleles. Full details of all the SNPs are in Supplementary Table 1.

### Main analyses

We firstly performed linear/logistic regression to examine the associations between SNPs for HbA<sub>1c</sub> and diabetes, and all of our outcomes of interest in PLINK and secondly, to examine the associations between SNPs for RT and diabetes and HbA<sub>1c</sub>. Then, inverse-variance weighted (IVW) MR was implemented as our main model. This approach calculates the effect of a given exposure (e.g. diabetes) on an outcome of interest (e.g. visual memory) by taking an average of the genetic variants' ratio of variant-outcome ( $SNP \rightarrow Y$ ) to variant-exposure ( $SNP \rightarrow X$ ) relationship estimated using the same principles as a fixed-effects meta-analysis [17]. We also performed standard MR sensitivity analyses, including MR-Egger regression (yields an intercept term which indicates the presence or absence of unbalanced horizontal pleiotropy)[18] and the weighted median estimator (WME, has the ability to yield more robust estimates when up to 50% of the genetic variants are invalid)[19]. Identical MR analyses were performed for diabetes (163 SNPs), HbA<sub>1c</sub> (52 SNPs) and: reaction time, visual memory, white matter hyperintensity volume, hippocampal volume and AD. Additionally, for reaction time and visual memory only, we repeated the MR analyses using only 16 glycaemic HbA<sub>1c</sub> SNPs. We did not perform these analyses for our other outcomes due to the likelihood of imprecision because of substantially reduced sample sizes. For bidirectional analysis, we used reaction time SNPs to investigate associations with HbA<sub>1c</sub> and diabetes.

### MR assumption checks

MR has three strict assumptions that must be met for study results to be valid:

- I) The association between the genetic variants for the exposure and the exposure itself must be strong and robust (this means that these associations have usually been replicated and validated via genome-wide association studies – GWAS –). *This assumption was met because our genetic variants for diabetes, HbA<sub>1c</sub> and reaction time (RT) were all from large-scale recent published GWAS. However, for the RT SNPs only, as there was concern about weak instrument bias, we additionally included*

*an MR-Egger Simulation Extrapolation (SIMEX)[20] sensitivity analysis, which we report in the Results section.*

- II) The association between the genetic variants (for the exposure) and the outcome must only be via the exposure under study, otherwise this is known as unbalanced horizontal pleiotropy and biases MR results. *This assumption was assessed using the methods detailed below, including MR-Egger.*
- III) There should not be an association between the genetic variants (for the exposure) and common confounders of the relationship under study (e.g. for diabetes and cognitive function, the diabetes SNPs should not be associated with factors such as smoking). *We checked this assumption by regressing multiple confounders (BMI, deprivation, systolic blood pressure, total cholesterol and smoking) on the diabetes, HbA<sub>1c</sub> and RT SNPs. We applied a Benjamini-Hochberg false discovery rate (BH-FDR) of 0.25 to account for multiple testing.*

## Results

### *Associations between diabetes/HbA<sub>1c</sub>, reaction time, and visual memory*

Diabetes was not associated with reaction time or visual memory using IVW and these results were consistent with MR-Egger and WME approaches (Table 1). HbA<sub>1c</sub> was not associated with reaction time using IVW and MR-Egger, but the weighted median showed evidence of an association, with every unit increase in HbA<sub>1c</sub> (mmol/mol) associated with a 2% faster reaction time [ $\exp(\beta)=0.98$ , 95% CI=0.98; 0.99]. When restricted to the 16 glycaemic SNPs, there was no evidence of an association with RT (Table 1). Using all 52 SNPs, the weighted median estimator suggested an association between HbA<sub>1c</sub> and visual memory [ $\exp(\beta)=1.06$ , 95% CI=1.05; 1.07], but no association under IVW and MR-Egger, (Table 1). When restricted to the 16 glycaemic SNPs, the MR-Egger estimate was larger (6%) than the IVW (2%) and WME (1%) effects (Table 1).

*Associations between diabetes/HbA<sub>1c</sub> and hippocampal and white matter hyperintensity volume and AD*

Diabetes was not associated with hippocampal or white matter hyperintensity volume, or AD using IVW, MR-Egger, or WME approaches (Table 2). Using the 52-SNP genetic instrument there was no evidence of associations between HbA<sub>1c</sub> and white matter hyperintensity volume or hippocampal volume (Table 2). Both HbA<sub>1c</sub> and diabetes appeared to have weak associations with AD using conventional IVW MR (OR (95% CI) 0.94 (0.47,1.86) and 0.97 (0.93,1.03), respectively), but these did not reach the conventional statistical significance threshold.

*Bidirectional analyses: reaction time and diabetes/HbA<sub>1c</sub>*

In the bidirectional analyses, we observed no association between RT and HbA<sub>1c</sub>, or between RT and diabetes (Table 3). All MR approaches (including MR-Egger-SIMEX for weak instruments) produced consistent results.

*Results from additional MR assumption checks*

We performed MR-Egger SIMEX alongside the conventional IVW MR to address issues with weak instruments in relation to the reaction time SNPs. Additionally, we checked that our genetic instruments for diabetes, HbA<sub>1c</sub> and RT were not associated with common confounders; When we regressed BMI, socioeconomic deprivation, systolic blood pressure, total cholesterol and smoking on the diabetes, HbA<sub>1c</sub> and RT SNPs we observed no associations using a Benjamini Hochberg false discovery rate (BH-FDR) of 0.25 to account for multiple testing (Electronic Supplementary Tables 2-4). Also, our MR-Egger intercept p-values were >0.05, which reassured us that there was unlikely to be unbalanced horizontal pleiotropy between our genetic instruments and outcomes of interest, with the exception of diabetes and AD (MR-Egger intercept p-value=0.04) (Table 2). However, when we used a 'leave-one-out' approach by removing the diabetes SNP that was most strongly associated with AD (rs2811712, p=0.01), the MR-Egger intercept p-value increased to 0.07, which indicated that this SNP is likely to be pleiotropic. The WME confirmed that all of our other MR-Egger results revealed no unbalanced horizontal pleiotropy, which were largely consistent with the IVW results.

## Discussion

In the first comprehensive Mendelian randomization study of both HbA<sub>1c</sub>/diabetes and brain health, we show that overall there is unlikely to be a causal relationship. However, we observed some evidence that increasing HbA<sub>1c</sub> was associated with poorer visual memory when using one method, but this was not replicated when using alternative MR methods. In bidirectional MR analyses, we found no relationship between reaction time and diabetes or HbA<sub>1c</sub>.

No previous studies have attempted to investigate, using MR, the association between HbA<sub>1c</sub> and any of the outcomes reported here. Only the WME approach showed that greater HbA<sub>1c</sub> related to faster RT. Other approaches did not, nor did we find any association when the instrument was restricted to the glycaemic variants, providing little support for a true association. However, there was some evidence of an association between increasing HbA<sub>1c</sub> and poorer visual memory using the WME. When we used the 16 glycaemic SNPs only there was more consistency across all MR approaches, but these associations were weak. This could indicate that there is in fact a causal association between HbA<sub>1c</sub> and visual memory, but perhaps better HbA<sub>1c</sub> genetic instruments and a more reliable memory measure are required to identify these effects more robustly. Bidirectional findings of RT and diabetes/HbA<sub>1c</sub> showed no evidence of causal relationships across all MR approaches.

We are the first to investigate diabetes/HbA<sub>1c</sub> and hippocampal and white matter hyperintensity volumes using an MR approach, but we observed no evidence of associations between these phenotypes. Although UKB has the largest brain imaging study in the world, perhaps a larger sample size would allow for more precise estimation of the relationships with these structural brain outcomes. However, the weak association between diabetes and AD only is at least supported by previous MR studies, which reported no impact of diabetes on AD [4–6] and thus, taking all of this evidence together, it is likely that diabetes does not exert a causal influence on risk of AD. Additional support for these findings comes from a recent study which suggests that, using a polygenic risk score for diabetes, the association between diabetes and cognitive state shown by observational studies [1] may be

explained by early life socioeconomic factors and childhood cognition, as well as educational attainment [21].

MR findings in this study were validated by checking that we met all three core assumptions. Assumption I was met by ensuring that we selected the best available genetic variants for our exposures (diabetes, HbA<sub>1c</sub> and reaction time) from the latest and most robust GWA studies. Assumption II was checked by performing standard sensitivity analyses under the MR-Egger model. Finally, we checked Assumption III by performing linear/logistic regressions between our genetic instruments for diabetes, HbA<sub>1c</sub> and reaction time and unobserved confounders. We show that after applying a BH-FDR multiple testing correction there were no associations between any of our SNPs and the above potential common confounders of the relationships under study.

Our study design had some limitations in terms of the reaction time and diabetes genetic variants, as the GWAS from which we selected these SNPs both contained UKB in their samples. For HbA<sub>1c</sub>, however, a two-sample MR design with no overlap was employed. We had low precision for MR analyses with AD, hippocampal and white matter hyperintensity volumes and larger samples are required for more robust conclusions. The AD diagnoses may be also be problematic, as accurate dementia diagnoses are extremely challenging to clinical experts, particularly amongst patients in the age range of UKB. However, previous UKB studies have used similar dementia diagnoses [22, 23], although the algorithm we relied on here additionally incorporates primary care data, alongside HES, mortality, self-report and nurse interview data. Our study findings were valid in the context of having met all three core MR assumptions and are thus, unlikely to suffer from issues related to population stratification, as all of the individuals in our sample were of white European descent. However, MR studies should also be performed to investigate the associations we report here in other ethnic groups, particularly given that the SNPs we used were derived using trans-ethnic GWA approaches.

In conclusion, our Mendelian randomization study of glycaemia and cognitive function, structural brain MRI measures and Alzheimer's dementia suggests that these associations are not likely to be causal. However, we observed that greater

HbA<sub>1c</sub> may worsen visual memory, but this finding, alongside all of the others we report, should be triangulated using other methods, in particular those relevant for causal inference.

### **Funding**

This work was conducted under the approved UK Biobank project number 7661. We thank the volunteer participants of the UK Biobank, and the UK Biobank researchers. This work was jointly funded by Diabetes UK and British Heart Foundation grant 15/0005250. KB holds a Sir Henry Dale Fellowship funded by Wellcome and the Royal Society (grant number 107731/Z/15/Z).

### **Duality of interest**

LS reports grants from BHF and Diabetes UK, during the conduct of the study; grants from Wellcome, grants from MRC, grants from NIHR, grants from GSK, grants from BHF, outside the submitted work and is a Trustee of the British Heart Foundation. NC reports grants from Diabetes UK, grants from British Heart Foundation, during the conduct of the study; personal fees from AstraZeneca, grants from Medical Research Council, outside the submitted work. The remaining authors declare that there are no conflicts of interest.

### **Contribution statement**

VG and NC conceived the idea and design of the study. VG performed all statistical analyses and wrote the manuscript. All authors contributed to the interpretation of the results, provided important intellectual input and approved the manuscript. VG guarantees the work carried out, had access to all of the data and takes responsibility for the integrity of the data and the accuracy of the data analysis. The UK Biobank data are publicly available to all bona fide researchers at <https://www.ukbiobank.ac.uk>.

### **References**

1. Rory J McCrimmon, Christopher M Ryan BMF (2012) Diabetes and Cognitive Dysfunction. *Lancet* 379:2291–99. <https://doi.org/10.1016/B978-0-12-398270->

4.00013-6

2. Ravona-Springer R, Luo X, Schmeidler J, et al (2010) Diabetes is associated with increased rate of cognitive decline in questionably demented elderly. *Dement Geriatr Cogn Disord* 29(1):68–74. <https://doi.org/10.1159/000265552>
3. Ojo O, Brooke J (2015) Evaluating the association between diabetes, cognitive decline and dementia. *Int J Environ Res Public Health* 12(7):8281–8294. <https://doi.org/10.3390/ijerph120708281>
4. Østergaard SD, Mukherjee S, Sharp SJ, et al (2015) Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. *PLoS Med* 12(6):1–16. <https://doi.org/10.1371/journal.pmed.1001841>
5. Hagenaaars SP, Gale CR, Deary IJ, Harris SE (2017) Cognitive ability and physical health: A Mendelian randomization study. *Sci Rep* 7(1):1–7. <https://doi.org/10.1038/s41598-017-02837-3>
6. Larsson SC, Traylor M, Malik R, Dichgans M, Burgess S, Markus HS (2017) Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis. *BMJ* 359:j5375. <https://doi.org/10.1136/bmj.j5375>
7. Kisler K, Nelson AR, Montagne A, Zlokovic B V. (2017) Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. *Nat Rev Neurosci* 18(7):419–434. <https://doi.org/10.1038/nrn.2017.48>
8. Fotuhi M, Do D, Jack C (2012) Modifiable factors that alter the size of the hippocampus with ageing. *Nat Rev Neurol* 8(4):189–202. <https://doi.org/10.1038/nrneurol.2012.27>
9. Lawlor DA (2016) Commentary: Two-sample Mendelian randomization: opportunities and challenges. *Int J Epidemiol* 45(3):908–915. <https://doi.org/10.1093/ije/dyw127>
10. Sudlow C, Gallacher J, Allen N, et al (2015) UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLoS Med* 12(3):1–10. <https://doi.org/10.1371/journal.pmed.1001779>
11. Bycroft C, Freeman C, Petkova D, et al (2018) The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562(7726):203–209. <https://doi.org/10.1038/s41586-018-0579-z>
12. Lyall DM, Cullen B, Allerhand M, et al (2016) Cognitive test scores in UK

- biobank: Data reduction in 480,416 participants and longitudinal stability in 20,346 participants. *PLoS One* 11(4):1–10.  
<https://doi.org/10.1371/journal.pone.0154222>
13. Alfaro-almagro F, Jenkinson M, Bangerter NK, et al (2018) NeuroImage Image processing and Quality Control for the first 10,000 brain imaging datasets from UK Biobank. *NeuroImage* 166(April 2017):400–424.  
<https://doi.org/10.1016/j.neuroimage.2017.10.034>
  14. Mahajan A, Taliun D, Thurner M, et al (2018) Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat Genet* 50(11):1505–1513.  
<https://doi.org/10.1038/s41588-018-0241-6>
  15. Davies G, Lam M, Harris SE, et al (2018) Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. *Nat Commun* 9(1):2098. <https://doi.org/10.1038/s41467-018-04362-x>
  16. Wheeler E, Leong A, Liu CT, et al (2017) Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. *PLoS Med* 14(9):1–30. <https://doi.org/10.1371/journal.pmed.1002383>
  17. Burgess S, Bowden J (2015) Integrating summarized data from multiple genetic variants in Mendelian randomization: bias and coverage properties of inverse-variance weighted methods
  18. Bowden J, Smith GD, Burgess S (2015) Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. *Int J Epidemiol* 44(2):512–525. <https://doi.org/10.1093/ije/dyv080>
  19. Bowden J, Davey Smith G, Haycock PC, Burgess S (2016) Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* 40(4):304–314.  
<https://doi.org/10.1002/gepi.21965>
  20. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA, Thompson JR (2016) Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I<sup>2</sup> statistic. *Int J Epidemiol* 1–14. <https://doi.org/10.1093/ije/dyw220>
  21. James, Sarah-naomi, Wong, Andrew, Tillin, Therese, Hardy, Rebecca, Chaturvedi, Nish, Richards M (2019) The effect of mid-life insulin resistance

- and type 2 diabetes on older-age cognitive state□: the explanatory role of early-life advantage. *Diabetologia* 61:1891–1900
22. Henry A, Katsoulis M, Masi S, et al (2019) Original article The relationship between sleep duration , cognition and dementia□: a Mendelian randomization study. 1–12. <https://doi.org/10.1093/ije/dyz071>
  23. Llewellyn DJ, Lourida I, Hannon E, et al (2019) Association of Lifestyle and Genetic Risk with Incidence of Dementia. *JAMA - J Am Med Assoc* 322(5):430–437. <https://doi.org/10.1001/jama.2019.9879>

Fig 1. Study design




Table 1. MR results for the relationship between diabetes/HbA<sub>1c</sub> and reaction time, and visual memory

	Outcome: Reaction time		Outcome: Visual memory	
Diabetes (163 SNPs)	exp( $\beta$ ) (95% CI)	Egger intercept p-value	exp( $\beta$ ) (95% CI)	Egger intercept p-value
IVW	1.00 (1.00;1.00)		1.00 (0.99;1.00)	
MR-Egger	1.00 (1.00;1.00)	0.342	0.99 (0.99;1.00)	0.164
WME	1.01 (1.01;1.01)		1.00 (0.99;1.00)	
HbA <sub>1c</sub> (52 SNPs)	exp( $\beta$ ) (95% CI)	Egger intercept p-value	exp( $\beta$ ) (95% CI)	Egger intercept p-value
IVW	1.00 (1.00;1.01)		0.99 (0.99;1.00)	
MR-Egger	1.00 (0.99;1.01)	0.311	1.00 (0.99;1.01)	0.531
WME	0.98 (0.98;0.99)		1.06 (1.05;1.07)	
HbA <sub>1c</sub> (16 SNPs)	exp( $\beta$ ) (95% CI)	Egger intercept p-value	exp( $\beta$ ) (95% CI)	Egger intercept p-value
IVW	0.99 (0.98;1.00)		1.02 (0.97;1.07)	
MR-Egger	1.00 (0.97;1.02)	0.609	1.06 (0.93;1.22)	0.476
WME	1.00 (0.98;1.01)		1.01 (0.94;1.09)	

Note. IVW= inverse-variance weighted, WME= weighted median estimator, exp( $\beta$ )= exponentiated beta (after log transformation), 95%CI= 95% confidence interval.

Table 2. MR results for the relationship between glycaemia and brain structure and Alzheimer's dementia

	Outcome: HV		Outcome: WMHV		Outcome: AD	
HbA <sub>1c</sub> (52 SNPs)	exp( $\beta$ ) (95% CI)	Egger intercept p-value	exp( $\beta$ ) (95% CI)	Egger intercept p-value	exp( $\beta$ ) (95% CI)	Egger intercept p-value
IVW	-0.02 (-0.10;0.06)		0.88 (0.73;1.07)		0.94 (0.47;1.86)	
MR-Egger	0.01 (-0.15;0.16)	0.965	0.79 (0.55;1.13)	0.478	0.74 (0.47;1.86)	0.665
WME	0.02 (0.11;0.15)		0.95 (0.70;1.27)		0.62 (0.22;1.79)	
Diabetes (163 SNPs)	exp( $\beta$ ) (95% CI)	Egger intercept p-value	exp( $\beta$ ) (95% CI)	Egger intercept p-value	exp( $\beta$ ) (95% CI)	Egger intercept p-value
IVW	0.00 (-0.01;0.01)		0.98 (0.93;1.03)		0.97 (0.89;1.06)	
MR-Egger	0.01 (-0.02;0.03)	0.594	1.00 (0.96;1.04)	0.632	1.17 (0.96;1.43)	0.043
WME	0.00 (-0.02;0.02)		0.98 (0.91;1.06)		1.08 (0.91;1.27)	

Note. IVW= inverse-variance weighted,  $\beta$ = unstandardized beta, exp( $\beta$ )= exponentiated  $\beta$  (after log transformation), OR= odds ratio, HV= hippocampal volume, WMHV= white matter hyperintensity volume, AD= Alzheimer's disease.

Table 3. MR results for the relationship between reaction time and HbA<sub>1c</sub> and diabetes

	Outcome: diabetes		Outcome: HbA <sub>1c</sub>	
Reaction time (43 SNPs)	$\beta$ /OR (95% CI)	Egger intercept p-value	$\beta$ /OR (95% CI)	Egger intercept p-value
IVW	1.00 (1.00;1.00)		-0.08 (-0.57;0.42)	
MR-Egger	1.00 (1.00;1.00)	0.457	-1.16 (-5.20;2.88)	0.596
MR-Egger-SIMEX	1.00 (1.00;1.00)	0.226	-0.24 (-0.94;0.46)	0.257
Weighted median	1.00 (1.00;1.00)		-3.03 (-8.01;1.95)	

Note. IVW= inverse-variance weighted,  $\beta$ = unstandardized beta, OR= odds ratio, MR-Egger-SIMEX= MR-Egger-Simulation extrapolation.